For the “yes”

Abstract

Medical specialist in Internal Medicine and Diabetology, Professor of Endocrinology, Metabolism and Nutrition, University Hospital, National University of Cuyo (UNcuyo), Faculty of Medical Sciences, Mendoza, Argentina

Insulin therapy remains the cornerstone of the treatment of type 1 diabetes (T1D). However, most people with T1D fail to achieve glycemic control goals (HbA1c). In recent decades, there have been increases in BMI, accompanied lpha increase in insulin resistance, often as inadequate insulin therapy. In addition, this group of patients has a high cardiovascular risk and a decrease in life expectancy.

T1D is a complex disease and therefore a more appropriate therapy must be proposed from the pathophysiological point of view, which accompanies hormonal replacement. These are arguments that justify studies with non-insulin drugs, complementary to insulin therapy, such as Metformin, DPP-4 inhibitors, GLP-1agosnists, Thiazonediones, alpha glucosidase inhibitors, SGLT2 inhibitors and amylin mimetics, in T1D. Some of these studies have shown benefits on HbA1c, BMI, glycemic variability and reduction in insulin requirement, although like all pharmacological therapy they are not without adverse effects. The use of some of these drugs could also provide benefits on cardiovascular and renal events.